PRODUCT INFORMATION

Risperidone E-Oxime

Item No. 22156

CAS Registry No.: 691007-09-7
Formal Name: 3-[2-[4-[(E)-(2,4-difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
MF: $C_{23}H_{28}F_2N_4O_2$
FW: 430.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Risperidone E-oxime is supplied as a solid. Risperidone E-oxime is slightly soluble in chloroform and methanol.

Description

Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.[1,2] Risperidone (Item No. 16329) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.[3,4] This second-generation antipsychotic was designed to antagonize both D_2 and 5-HT_{2A} receptors.[5,6] It has little effect on cholinergic and β-adrenergic receptors but does affect α_2-adrenergic and histamine H_1 receptors.[5,6]

References

1. Bharathi, C., Chary, D.K., Kumar, M.S., *et al.* Identification, isolation and characterization of potential degradation product in risperidone tablets. *J. Pharm. Biomed. Anal.* **46(1)**, 165-169 (2008).
2. Nejedly, T., Pilarova, P., Kastner, P., *et al.* Development and validation of rapid UHPLC method for determination of risperidone and its impurities in bulk powder and tablets. *Int. J. Res. Pharm. Chem.* **4(2)**, 261-266 (2014).
3. Colpaert, F.C. Discovering risperidone: The LSD model of psychopathology. *Nat. Rev. Drug Discovery* **2**, 315-320 (2003).
4. Rainer, M.K. Risperidone long-acting injection: A review of its long term safety and efficacy. *Neuropsychiatr. Dis. Treat.* **4(5)**, 919-927 (2008).
5. Fujimuro, M., Sawada, H., and Yokosawa, H. Production and characterization of monoclonal antibodies specific to multi-ubiquitin chains of polyubiquitinated proteins. *FEBS Letters* **349(2)**, 173-180 (1994).
6. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., *et al.* Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology* **14(2)**, 87-96 (1996).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM